Background: Comprehensive cancer care uses complementary approaches alongside specific anticancer therapy. Using a dedicated questionnaire, the Calista2 survey sought to assess the importance of supportive care and activities among lung cancer (LC) patients, how often these services are made available and offered, the utilization rate, and the frequency of unmet needs. Method: The 25 physicians who accepted to take part in the survey recruited 198 patients of whom 143 answered the patient-reported questionnaire. Patients meeting the inclusion criteria were adults already on specific therapy for advanced LC. The patient-reported questionnaires covered drug management of pain, fatigue, adverse effects of treatments (AE), and sleep disorders, social and psychological support, physical activities, and complementary and alternative medicines. Items were rated on a 0 e 10 scale. Questionnaires were collected between September 2016 and October 2017. Result: After exclusion of non-valid patient questionnaires, 134 were analyzed. The mean age of these patients was 64.3 years (SD:8.5). There were 62% men and 37% women. Patients perceived the management of pain, AE and fatigue as the three most important items (7.5, 7.2, 6.0) while counselling with regards to employment (1.7), spiritual support (2.6), art therapy (2.6), and support groups for patients' children (2.6) were the least important. Although most of the facilities were available at the point of care, complementary medicines, art therapy, and professional counselling were accessible for 29%, 33%, and 21%, respectively. Physicians frequently suggested pain and AE management (78%, and 75%, respectively), and diet counselling (51%). In contrast, fatigue management, sleep disorders, and sexual issues were less frequently addressed (35%, 44%, and 6%, respectively). Paradoxically, the four main unmet needs were management of fatigue, complementary medicines, psychological support for the patient's family and friends and relaxation techniques (32%, 25%, 20%, and 20%, respectively). Conclusion: These key findings highlight the fact that support for pain and for the AE of cancer treatment are available, suggested and used. In contrast, unmet needs expressed by the patients were either available but not used (fatigue management and psychological support for the patient's family and friends) or rarely available (complementary medicines and relaxation techniques).
greatest challenge in oncology today is how to reconcile improvements in the management of cancer with the exponentially increasing costs of new treatment and this is a very important barrier in low and middle income countries. The objective of this study was to assess the cost-effectiveness and economic impact of second-line treatment with nivolumab and pembrolizumab with and without the use of PD-L1 testing for patient selection in Colombia. Method: We designed a decision-analytic model to evaluate the cost-effectiveness of second-line immunotherapy versus docetaxel for advanced NSCLC. We considered the outcomes from randomized clinical trials (RCTs). Direct and indirect costs were retrieved with a colombian perspective. We followed standard recommendations for the conduct and reporting of health economic analyses. Primary endpoint were Incremental Cost Effectiveness Ratios (ICER), for treatment with nivolumab and pembrolizumab with and without PDL1 testing. Result: Nivolumab improved quality-adjusted life-years (QALY) by 0.417 among squamous tumors and 0.287 among non squamous tumors. The ICER were $135,093 COP and $179,391 COP, respectively. Pembrolizumab achieved a QALY gain of 0.346 and the ICER was $146,022 COP. The use of PD-L1 expression as a tailor biomarker for nivolumab among nonsquamous tumors improved incremental QALY by up to 157% and decreased the ICER by up to 61% compared with treating all patients. Considering a willingness to pay threshold of three times the Colombian Gross Domestic Product per capita, second-line immunotherapy was not cost-effective with or without patient selection by PD-L1 expression. Conclusion: Patient selection by PD-L1 expression increased cost-effectiveness of immunotherapy. Second-line immunotherapy was not cost-effective in Colombia due to its high cost. Taking into account the disparities in access to cancer innovative therapies, there is a need to promote strategies to reduce drug acquisition costs, such as price discrimination and the use of biosimilars or generics. Keywords: cost effectiveness, pharmacoeconomics, Inmunotherapy P2.15-19 Inequality of Access to Novel Lung Cancer Therapies in Europe H. O'Sullivan L. Coate University Hospital Limerick, Limerick City/IE Background: With an estimated incidence of over 449,000 cases per year, lung cancer is one of the most common malignancies in Europe. Over the last decade the landscape of lung cancer treatment has evolved. We have entered a new era of lung cancer treatment and high costs has led to disparities in lung cancer care among different European countries. There is evidence of discrepancy in access to cancer therapies in Europe however access to contemporary targeted agents and immunotherapy for lung cancer hasn't been studied. We analysed the reimbursement dates of novel lung cancer therapies in Europe. Method: The lung cancer therapies investigated include the tyrosine kinase inhibitors (TKI) alectinib, ceritinib, and crizotinib. Immunotherapy agents nivolumab, pembrolizumab and atezolizumab were also researched. National reimbursement dates of these drugs of these drugs in 29 European countries were obtained from national resources and from the pharmaceutical companies' affiliates. Result: As of February 2018, Crizotinib was reimbursed in 24/29 (83%) of countries. Ceritinib was reimbursed in 21/29 (72%) of countries while Alectinib was reimbursed in 12/29 (41%) countries. Pembrolizumab and Nivolumab were reimbursed for previously treated NSCLC in 21/29 (72%) and 18/29 (62%) countries respectively. Atezolizumab was reimbursed in 7/29 (24%) countries for previously treated NSCLC patients. Pembrolizumab for first line treatment of NSCLC was reimbursed in 20/29 (69%) countries, while in 9/29 (31%) (all Eastern European Countries) not reimbursed. Background: Clinical guidelines for metastatic non-small cell lung cancer (NSCLC) increasingly include molecular testing for actionable biomarkers related to immuno-oncology (IO) use in lung cancer patients. While precision therapies targeting the PD-1/PD-L1 pathway have the potential to improve patient response rates, there is ambiguity regarding optimal biomarker testing and care coordination for NSCLC patients. To address this disparity in health care delivery, an online education program on molecular testing related to immunotherapies was developed for multispecialty providers. Learner responses were evaluated to determine the educational impact. Method: A thoracic surgeon, medical oncologist and pathologist developed a curriculum to address the current diagnostic landscape in IO, the value of testing and patient response rates, and how to optimize care coordination and communication among multispecialty team members. In February 2018, a live-online 1-hour video panel discussion with slides, participant polling, and live questions was produced and made available on-demand. Survey responses (pre-test, post-test, 4 weeks post-activity), polling responses, and live questions were tracked to measure knowledge gaps, lessons learned, and educational needs. Demographic information was collected for generalizability. Result: Seventy-one learners participated in the live webinar; 64 learners on-demand (n¼135). Learners were actively engaged for an average of 35.19 minutes (out of 52 minutes). Learners represented 11 unique disciplines and specialties. Most learners indicated specializing in oncology (55%), were practicing physicians (31%), and saw 1-10 new patients on an IO therapy each week (72%) in a hospital-based setting (35%). Seven audience questions were asked prior to, and during the live session. Thirty of 135 learners completed all pre/post/follow-up surveys, 96% of which reported they will actively utilize the knowledge gained into their clinical practice. Because of the education provided, learners reported improvements in their ability to: identify patients to test and treat with IO (75%), comprehend the current diagnostic landscape in IO (100%), and optimize communication and coordination of IO testing (100%). Learners also demonstrated improved comprehension via case study by identifying the optimal next step for a NSCLC clinical stage I patient referred by an oncologist for surgical resection who was found to have pleural disease intraoperatively. Conclusion: The rapid expansion of cancer immunotherapy-based options for patients with lung cancer requires providers to stay abreast on guidelines related to molecular testing. Continued refinement of care coordination practices between multispecialty team members and education on the value of molecular testing is recommended to improve the diagnosis and appropriate treatment decisions for patients with lung cancer We recently investigated contemporary practice in post-resection lung cancer surveillance, between the Society of Thoracic Surgeons (STS) and the European Society of Thoracic Surgeons (ESTS) updating a published STS survey and showed a wide variance of practice. In order to understand better the role of socio-demographics on this divergence, we aim to compare these patterns to those of members of the Japanese Association for Chest Surgery(JACS) as well as surveillance attitudes across these regions. Method: A survey identical to the one conducted in 1995 among STS members was administered via mail or electronically to members of the STS, ESTS and JACS requesting responses from those treating NSCLC. Goodness of fit tests were used to compare profiles of respondents and attitudes toward testing between groups. Multivariable logistic regression was performed to examine for predictors of guideline concordant surveillance with CT. Result: A total of 2978 STS member (response rate 7.8%, n¼234), 1450 ESTS members (response rate 8.4%, n¼122) and 272 JACS (response rate 40,8%, n¼111) members were surveyed. All three societies reported similar use of history and physical examination for asymptomatic patients (75%vs78%vs73%p¼0.52). Rate of guideline-recommended surveillance CT was reported highest among ESTS respondents for stage I patients (22% ESTS, 3% STS and 6% JACS members, p<0.01). However, both JACS and ESTS respondents reported higher rates of use of non-guidelines-recommended tests compared to STS respondents which persisted on adjusted analyses. In particular, JACS and ESTS respondents reported significantly higher use of brain MRI Regarding attitudes towards surveillance, more JACS and ESTS members either "agree" or "strongly agree" that routine testing for NSCLC recurrence results in potentially curative treatment (ESTS:86%, STS:70%, JACS:90% p<0.01). Similarly, JACS and ESTS respondents believe that surveillance would identify a curable second primary NSCLC (ESTS:94%, STS:84%, JACS:100% p<0.01) and that current literature documents definitive survival benefits from routine follow-up testing (ESTS:57%, STS:30%, JACS:62% p<0.01). Conclusion: The Japanese attitude towards surveillance is similar to that of ESTS members potentially highlighting significant differences between European and Asian surgeons compared to STS members and may be the underpinnings of routine use of nonguideline concordant surveillance. These differences clearly highlight the need of better prospective studies and joint
